NCT01445379View on ClinicalTrials.gov

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 1, 2007

Primary Completion Date

April 18, 2014

Study Completion Date

November 13, 2015

Conditions
SarcomaWilm's TumorLymphomaNeuroblastoma
Interventions
DRUG

Ipilimumab

Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg

Trial Locations (3)

10021

Memorial Sloan Kettering Cancer Center, New York

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01445379 - Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | Biotech Hunter | Biotech Hunter